ArticleJournal of ophthalmology2026
Evaluating Pilocarpine 1% Eye Drops in Presbyopia: A Triple-Blinded Randomized Trial.
Article in Journal of ophthalmology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Evaluating Pilocarpine 1% Eye Drops in Presbyopia: A Triple-Blinded Randomized Trial.Journal of ophthalmology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Presbyopia is an age-related condition that affects near vision and daily activities. Although several correction methods are available, each has certain limitations, leading to interest in pharmacologic alternatives such as pilocarpine eye drops. This study evaluates the safety and clinical effectiveness of 1% pilocarpine eye drops, as data on its use remain limited. Material and Method: A triple-blinded clinical trial was conducted in 2024 in Yazd, Iran, enrolling 60 presbyopic patients aged 40-60 years. The study was approved by the Iranian Registry of Clinical Trials. Participants received either 1% pilocarpine eye drops or a placebo daily for 30 days. Their visual acuity-both near and distance-was assessed under mesopic conditions at six intervals. Throughout the trial, any side effects and treatment satisfaction were monitored. Statistical analysis was performed, considering results significant if Results: In this study, the treatment group demonstrated a significant improvement in uncorrected near visual acuity (UNVA) at all follow-ups compared to the placebo group, peaking 1 hour after treatment ( Discussion: This study supports previous research by showing improvements in UNVA, a quick onset of effects, and an acceptable safety profile. However, there was a slight worsening in UDVA; this may be due to higher initial measurements or temporary effects. Unlike many past trials, this study utilizes a rigorous triple-blinded design and measures effects at six different times, giving a thorough look at both the onset and duration of effects. Conclusion: A 1% pilocarpine treatment has been found to significantly improve near vision in presbyopic patients, with minimal side effects and high patient satisfaction.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.